Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul;21(7):1003-1004.
doi: 10.1513/AnnalsATS.202404-439ED.

Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Real-World Evidence Highlights Need for Worldwide Access

Peter J Barry  1 , Andrew M Jones  1   2
Affiliations
Editorial

Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Real-World Evidence Highlights Need for Worldwide Access

Peter J Barry et al. Ann Am Thorac Soc. 2024 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Kessler WR, Andersen DH. Heat prostration in fibrocystic disease of the pancreas and other conditions. Pediatrics . 1951;8:648–656. - PubMed
    1. Burgel PR, Paillasseur JL, Durieu I, Reynaud-Gaubert M, Hamidfar R, Murris-Espin M, et al. Multisystemic effects of elexacaftor–tezacaftor–ivacaftor in adults with cystic fibrosis and advanced lung disease Ann Am Thorac Soc 2024211053–1064.. - PubMed
    1. Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, et al. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. J Cyst Fibros . 2022;21:489–496. - PubMed
    1. Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al. French Cystic Fibrosis Reference Network Study Group Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med . 2021;204:64–73. - PubMed
    1. Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, et al. VX17-445-105 Study Group Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J . 2023;62:2202029. - PMC - PubMed

MeSH terms